about us

press release

contact

Home

Executives

Acquisitions/Mergers

Funding

FDA Updates

Clinical Trials

Medical Device News

Aristea Therapeutics Announces Key Leadership Appointments

Ciara Kennedy, Founder, President and Chief Executive Officer of Sorriso Pharmaceuticals, is Chair of the Board of Directors of Aristea Therapeutics and Fabio Magrini, clinical research leader in chronic inflammatory and autoimmune diseases, is Executive Medical Director of Aristea Therapeutics

Latest Posts

Accuredit Therapeutics and N1 Life Form a Joint Venture Named ‘Napoltec’, Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical...

"We are very pleased to establish a new joint venture, Napoltec, with N1 Life, which will be featuring complementary in mutually pursuing gene therapy drug development. The N1 Life team led by Dr. Zang and Prof. Wender has accumulated years of research and development experience in novel delivery systems.

FDA Releases Federal Interagency Working Group Scientific Opinions on Testing Methods for Asbestos in Talc-Containing Cosmetic Products

Release of the white paper concludes the efforts of the IWGACP. The FDA will consider the scientific opinions presented in the white paper, including having it peer-reviewed, as part of its overall efforts to help ensure the safety of talc-containing cosmetic products.

Hekka Labs Introduces the First Decentralized Chronic Disease Data Management Ecosystem in South Asia

Hekka has cemented initial partnerships with 3 Indian healthcare solution providers, Curisin, a healthcare company with a wide network of 30 million patients and 40,000 partnered doctors which as recently agreed to provide a minimum of 1.5 million medical records in 2022.

Impact NRS LLC Creates RumenEra Inc to Develop and Commercialize High-Impact Rumen Microbiome Applications in a Joint Collaboration with National Institute for Biotechnology in...

Mr. Salman continues "RumenEra is committed to the creation of a global reference standard for the rapid measurement of net feed efficiency, as well as creating products that can be applied to ruminants to optimize their efficiency while decreasing environmental burdens, naturally and healthily, for both the animals and their ecosystems."

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat rare serious inflammatory diseases, today announced the appointment of Ciara Kennedy as Aristea Therapeutics’ Chair of the Board of Directors and Fabio Magrini as Executive Medical Director.

James M. Mackay, Ph.D., President and CEO of Aristea, commented, “Ciara and Fabio are invaluable members of our Board and management teams, respectively. Both scientists, collectively bring decades of experience in our industry to the company. Their contributions moving forward will be crucial, as we move our lead drug, RIST4721, through the clinic for palmoplantar pustulosis and additional inflammatory and autoimmune diseases.”

“I’m delighted to expand my role with Aristea at such a dynamic time for the company,” said Dr. Kennedy. “Following last year’s successful Series B financing and our auspicious collaboration agreement with Arena Pharmaceuticals, Aristea is well-positioned to make significant strides in developing RIST4721 for a wide range of neutrophil-mediated inflammatory indications.”

“It is truly an honor to join Aristea and be part of such an exceptional team,” said Dr. Magrini. “I’m humbled and excited by the opportunity to contribute to the success of such a dynamic and innovative organization dedicated to easing the suffering of patients in a growing range of inflammatory and autoimmune diseases with no or few treatment options.”

Dr. Kennedy, currently a member of Aristea’s Board of Directors, is an experienced executive with a proven track record of delivering significant results and advancing therapeutic and diagnostic programs across multiple therapeutic areas and stages of development in the biotech industry. She is the founder, President and Chief Executive Officer of Sorriso Pharmaceuticals. Previously, Dr. Kennedy was President and Chief Executive Officer of Amplyx Pharmaceuticals until the company’s acquisition by Pfizer, where she successfully raised over $150M to develop novel treatments for immunocompromised patients. Dr. Kennedy served as Chief Operating Officer at Lumena Pharmaceuticals until the company’s acquisition by Shire Pharmaceuticals and as Vice President, Head of Cholestatic Liver Disease at Shire post-acquisition. She has also served in several positions at Cypress Bioscience Inc., where she played a key role in the company’s FDA approval and launch of Savella® for Fibromyalgia; as well as at the Program and Alliance department of Biogen Idec. A Ph.D. scientist by training, Dr. Kennedy received her doctorate at the Queen’s University of Belfast, Northern Ireland.

Dr. Magrini brings 20 years of industry experience designing and implementing clinical programs in chronic inflammatory and autoimmune diseases across several therapeutic areas, including neurology, rheumatology, nephrology, and dermatology, to his role. He previously served as Principal Medical Director, Neuroimmunology and Medical Director, Neuroscience at Genentech Inc., and as Senior Medical Director at MedImmune, LLC. He gained earlier experience as a researcher at Roche and Pfizer Inc. A Rome native, Dr. Magrini qualified in Medicine and Surgery at University of L’Aquila, Italy, and later moved to England where, before joining the pharmaceutical industry, he worked at Cambridge University Department of Pathology, Human Molecular Genetics, and at Addenbrooke’s Hospital as a Clinical Fellow in Dermatology.

Latest Posts

Learn More

spot_img

Don't Miss